SK Life Science Labs Experts Unveil Latest Scientific Findings at Keystone Symposia on Epigenetic Mechanisms and Cancer Treatment, and the 2nd Annual Molecular Glue Drug Development Summit KING OF PRUSSIA, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, Co., Ltd., showcased its cutting-edge targeted...

SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit KOREA and KING OF PRUSSIA, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SK Life Science Labs (formerly Proteovant Therapeutics) a subsidiary of SK Biopharmaceuticals, today will present preclinical data...

SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics KOREA and KING OF PRUSSIA, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of...

SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and MOPED™ Molecular Glue Screening Platform at the 20th Annual Discovery on Target Conference KOREA and KING OF PRUSSIA, Pa., Sept. 26, 2023 (GLOBE NEWSWIRE) -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of...